COPD

High-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B did not have significant correlations with chronic obstructive pulmonary disease.

The authors found that humidity, cold and heat waves, and air pollution led to a higher likelihood of asthma- and chronic obstructive pulmonary disease (COPD)-related hospitalizations.

Compared prednisolone alone, benralizumab with and without prednisolone resulted in fewer treatment failures and stronger VAS scores.

During a 15-year period, 1 in 5 older adults living with COPD received a shingles vaccine.

In the analysis, 34.7% of commercially insured patients with chronic obstructive pulmonary disease or asthma received an influenza vaccination.

Dupilumab is the first biologic medicine for patients with chronic obstructive pulmonary disease to be approved in the US.

The exhaled breath condensate mask was able to successfully monitor and accurately detect breath for nitrate in patients with asthma or chronic obstructive pulmonary disease.

As dupilumab garners positive clinical trial results in patients with chronic obstructive pulmonary disease, it is increasingly important that pharmacists educate themselves on the treatment.

After over 2 decades, the first inhaled product with a novel mechanism of action has been approved by the FDA for the treatment of chronic obtrusive pulmonary disorder.

Patients with undiagnosed asthma or COPD who received usual care from their primary providers were more likely to visit the hospital or specialists because of respiratory illness.

By improving health insurance coverage and cost of inhalers, such as out-of-pocket caps, access to care can be increased. Some companies are aiming to improve access by implementing price caps.

For patients with a blood eosinophil count of 150 cells/µL or greater, tezepelumab had a significant reduction of approximately 37% in the rate of moderate or severe exacerbations.

A pharmacist-led transitions of care program reduced chronic obstructive pulmonary disease readmissions by implementing guideline-based inhaler prescribing and addressing medication adherence barriers, decreasing 30-day readmission rates.

The Asthma and Allergy Foundation of America applauded the efforts by AstraZeneca, saying accessibility and affordability can help reduce racial disparities in asthma.

The company has announced that the first participants have also been dosed in the ATHLOS phase 3 clinical trial, investigating budesonide/glycopyrronium/formoterol fumarate (Breztri Aerosphere).

A 12-week supplement improved systolic blood pressure in this patient group more than placebo.

The efficacy of biologics suggests a potential for biologic-based treatment for patients with asthma-chronic obstructive pulmonary disease overlap.

The new understanding of immune cells could not only contribute to the development of lung disease treatments, but treatments for other organ systems as well.

The study authors note that interventions to reverse frailty, such as screening and assessments to identify issues, can help in the management of COPD and asthma and lead to better prognoses.

Patients with uncontrolled chronic obstructive pulmonary disease and type 2 inflammation had significantly better lung function at least a year into dupilumab regimen.

More individuals who used e-cigarettes have reported pulmonary diseases compared with those who never smoked, including asthma.

A patient with lung adenocarcinoma who was treated with an immune checkpoint inhibitor developed symptoms related to asthma and breathing obstruction.

The study authors said that, to their knowledge, this will be the first systematic review focusing on the effects of cognitive interventions for those with chronic respiratory diseases.

The treatment improved lung function at 12 weeks and quality of life at 4 weeks.

But analysis does suggest a small increase in risk for individuals who used cigarettes and electronic nicotine delivery systems together.

Data show that dose-response relationships and long-term safety of ICS in people with chronic obstructive pulmonary disease are unclear and require further investigation.

Regeneron and Sanofi’s Dupilumab is the first biologic to demonstrate a clinically meaningful and statistically significant reduction in exacerbations compared with the placebo.

Study findings confirmed that in asthma, chronic obstructive pulmonary disease, HIV, and influenza, census data differed from the epidemiological data.

Variety of interventions improves morbidity, mortality, associated costs for patients with chronic obstructive pulmonary disorder.